FIGURE 8.

Schematic diagram for the rationale, design and characterization of Aβ fibril inhibitors from herbal medicines. The incubation of Aβ (1–42) solution with TCMs extract. Analysis of the pre-incubated Aβ (1–42)-TCM extract mixture using Agilent 6230 UHPLC-DAD-TOF/MS instrument. Chemical analytical prediction on the binding propensity of the compounds by UHPLC-DAD-TOF/MS. Identification of the Aβ (1–42) binding chemical components from TCMs with their accurate mass identified and confirmed from literatures. Bioassay-validation of the Aβ (1–42) peptide-binding propensity of the identified compounds.